ORAL PHOSPHATE BINDERS FOR THE MANAGEMENT OF SERUM PHOSPHATE LEVELS IN DIALYSIS PATIENTS
- 1 March 2009
- journal article
- review article
- Published by Wiley in Journal of Renal Care
- Vol. 35, 65-70
- https://doi.org/10.1111/j.1755-6686.2009.00052.x
Abstract
Hyperphosphataemia is an inevitable consequence of end stage chronic kidney disease and is present in the majority of dialysis patients. Hyperphosphataemia is statistically associated with increased cardiovascular mortality among dialysis patients. Dietary restriction of phosphate and current dialysis modalities are not sufficiently effective to maintain serum phosphate levels within the recommended range so that the majority of dialysis patients require oral phosphate binders. However, benefits of achieving the recommended range have yet to be demonstrated prospectively. Unfortunately, conventional phosphate binders are not reliably effective and are associated with a range of limitations and side effects. Aluminium containing agents are highly efficient but no longer widely used because of well-established and proven toxicity. Calcium-based salts are inexpensive, effective and most widely used but there is now concern about their association with hypercalcaemia and vascular calcification. Sevelamer hydrochloride and lanthanum carbonate are non-aluminium, calcium-free phosphate binders. They are effective and reasonably well tolerated, but still do not control phosphate levels in all patients. Patient education programmes have been shown to be a useful and effective method of improving achievement of serum phosphate targets.Keywords
This publication has 37 references indexed in Scilit:
- Gastrointestinal Absorption of Aluminium in Chronic Renal InsufficiencyExpanded Hemodialysis: Innovative Clinical Approach in Dialysis, 2015
- Systemic lanthanum is excreted in the bile of ratsToxicology Letters, 2007
- Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled studyNephrology Dialysis Transplantation, 2005
- Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysisClinical Nephrology, 2004
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patientsKidney International, 2003
- Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney International, 2002
- Reduced Risk of Hypercalcemia for Hemodialysis Patients by Administering Calcitriol at NightAmerican Journal of Kidney Diseases, 1992
- Death Risk in Hemodialysis Patients: The Predictive Value of Commonly Measured Variables and an Evaluation of Death Rate Differences Between FacilitiesAmerican Journal of Kidney Diseases, 1990
- Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysisKidney International, 1982